

SECTION III-A

Joint Exhibit List

Any description of a document on this Exhibit List is provided for convenience only and shall not be used as an admission or otherwise as evidence regarding the listed document or any other listed document.

The listing of an Exhibit does not constitute an admission as to the admissibility of the Exhibit (i.e., a waiver of any applicable objection). Each party reserves the right to object to the relevance or admissibility of any Exhibit offered by the other party, at the time such Exhibit is offered, in view of the specific context in which such Exhibit is offered, or for any other reason as set forth in the Federal Rules of Evidence or other applicable principles of law.

| JTX | Document Date | Description | Beg Bates | End Bates | Hospira Objections | FK Objections |
|-----|---------------|---|-------------------|-------------------|--------------------|---|
| | | U.S. Patent No. 8,648,106 | | | | |
| | | U.S. Patent No. 9,616,049 | | | | |
| | | U.S. Patent No. 8,455,527 | | | | |
| | | U.S. Patent No. 9,320,712 | | | | |
| | | US Patent No. 8,242,158 | | | | |
| | | US Patent No. 8,338,470 | | | | |
| | 4/22/2013 | File History of U.S. Patent No. 8,648,106 | HOSPIRA_00001039 | HOSPIRA_00001178 | F, H, P | |
| | | Prosecution History for US Patent 9,616,049 | HOSPIRA_02500339 | HOSPIRA_02500921 | F, H, P | |
| | 11/15/2012 | File History of U.S. Patent No. 8,455,527 | HOSPIRA_00000707 | HOSPIRA_00001038 | F, H, P, R | |
| | | Prosecution History for US Patent 9,320,712 | HOSPIRA_02499862 | HOSPIRA_02500338 | F, H, P, R | |
| | 1/4/2012 | File History of U.S. Patent No. 8,242,158 | HOSPIRA_00000001 | HOSPIRA_00000316 | F, H, P, R | |
| | 7/3/2012 | File History of U.S. Patent No. 8,338,470 | HOSPIRA_00000317 | HOSPIRA_00000706 | F, H, P, R | |
| | | ANDA Section 1.12.12 Comparison Between Generic Drug and RLD | FK-DEXMED 0000050 | FK-DEXMED 0000051 | F, H, P, X, Y | R, F |
| | | NDA No. 21-038 review package | FK-DEXMED 0005774 | FK-DEXMED 0005819 | | |
| | 12/17/1999 | NDA No. 21-038 Final Printed Labeling | FK-DEXMED 0005820 | FK-DEXMED 0005833 | F, H, P, D | |
| | | President's Message, "Dexmedetomidine and Hextend: Their Role in Trauma Care," International TraumaCare, 17(1):4-5 (2007) ("Cain") | FK-DEXMED 0005834 | FK-DEXMED 0005835 | F, H, P | |
| | | Palmgren, "Drug Adsorption in Plastic Containers and Retention of Drugs in Cultured Cells Under In Vitro Conditions," 64 Eur. J. Pharm. and Biopharmaceutics 369, 369-378 (2006) ("Palmgren") | FK-DEXMED 0005841 | FK-DEXMED 0005850 | F, H, P | |
| | 4/6/2004 | US Patent No. 6,716,867 ("Aantaa") | FK-DEXMED 0005898 | FK-DEXMED 0005908 | F, H, P | |
| | November 2011 | J. Fanikos, "Premixed Products Improve Safe Medication Practices," Pharmacy Practice News (November 2011) ("Fanikos") | FK-DEXMED 0006017 | FK-DEXMED 0006018 | F, H, P | |
| | | Remington: The Science and Practice of Pharmacy, 21st edition (published 2006) ("Remington") | FK-DEXMED 0006019 | FK-DEXMED 0006032 | F, H, P | |
| | 1978 | Walter F. Stanaszek et al., Comparison of Drug Stability in Glass Versus Plastic Containers: Analysis of Prefilled Syringe Admixtures, PROC. OKLA. ACAD. SCI. 58:102-105 (1978) ("Stanaszek") | FK-DEXMED 0006033 | FK-DEXMED 0006036 | F, H, P | |
| | 4/9/2010 | De Giorgi et al., "Risk and pharmaco-economic analyses of the injectable medication process in the pediatric and neonatal intensive care units," Int'l J. Quality in Health Care, Vol. 22, No. 3 (Apr. 9, 2010) ("De Giorgi") | FK-DEXMED 0006090 | FK-DEXMED 0006098 | F, H, P | |
| | | Lavoisier Sodium Chloride 09% injectable solution | FK-DEXMED 0006133 | FK-DEXMED 0006134 | F, H, P | |
| | 11/25/2009 | Gregory A. Sacha, et al., Practical Fundamentals of Glass, Rubber, and Plastic Sterile Packaging Systems, PHARM. DEV. TECH. 15(1):6-34 (2010) ("Sacha") | FK-DEXMED 0195975 | FK-DEXMED 0196004 | F, H, P | |
| | | Sharp T.R., Calculated Carbon-Hydrogen Bond Dissociation Enthalpies for Predicting Oxidative Susceptibility of Drug Substance Molecules. INT. J. PHARM. 418:304-317 (2011) ("Sharp") | FK-DEXMED 0197882 | FK-DEXMED 0197895 | F, H, P | |
| | 10/9/2013 | Email chain re FINAL signed docs NPA | FK-DEXMED0088049 | FK-DEXMED0088060 | F, H | R, AU, F, Y (bates range includes attachment) |
| | 4/12/2004 | Separation and Distribution Agreement - Abbott Laboratories and Hospira Inc | FK-DEXMED0196497 | FK-DEXMED0196526 | Au, F, H, P, X | |
| | 8/8/2013 | Email re Cross-Functional NPA Meeting on Aug 08, 2013: Meeting minutes | FX-DEXMED0193120 | FX-DEXMED0193126 | F, H, K | P, R, Y (bates range includes attachment) |

Joint Exhibit List

| JTX | Document Date | Description | Beg Bates | End Bates | Hospira Objections | FK Objections |
|-----|---------------|---|------------------|------------------|--------------------|---|
| | 5/28/2015 | Email re Dexmed RTU PHB | FX-DEXMED0194719 | FX-DEXMED0194754 | F, H, K | P, R, Y (bates range includes attachment) |
| | 11/30/1999 | FDA Memorandum by Cynthia G. McCormick, M.D. | HOSPIRA_00000394 | HOSPIRA_00000403 | F, H, P | H, R |
| | 10/12/2012 | NDA 021038 Prior Approval Supplement re 50 ml and 100 ml premix | HOSPIRA_00001187 | HOSPIRA_00002305 | V, X, Y | H, R |
| | 12/14/1998 | NDA 21-038 Section 4.3 portions | HOSPIRA_00006525 | HOSPIRA_00006853 | Y, F, K | H, R |
| | 12/18/1998 | NDA 21-038 Section 4.3 portions (cntd.) | HOSPIRA_00006854 | HOSPIRA_00007185 | F, K | H, R |
| | 12/14/1998 | NDA 21-038 re Phase I studies | HOSPIRA_00132543 | HOSPIRA_00132920 | F, H, P | H, R |
| | 3/17/1989 | Farmos Group Ltd., Dexmedetomidine IND | HOSPIRA_00308480 | HOSPIRA_00311241 | V, AU | |
| | 2/28/1990 | Letter and enclosures re Investigational New Drug Application 32,934: Dexmedetomidine hydrochloride injection | HOSPIRA_00311242 | HOSPIRA_00311415 | AU, X | R |
| | 3/19/1990 | Letter and enclosures re Investigational New Drug Application 32,934: Dexmedetomidine hydrochloride injection | HOSPIRA_00311416 | HOSPIRA_00312432 | AU, X | R |
| | 10/10/1990 | IND 32,934 Clinical Protocol CL-0690 | HOSPIRA_00312433 | HOSPIRA_00312522 | F, P | |
| | February 1991 | Stability data re Batch OK 029 L1 | HOSPIRA_00312601 | HOSPIRA_00312607 | K, AU | R, X |
| | 5/10/2004 | Letter from K. Patterson to FDA re IND 32,934 - Precedex® (Dexmedetomidine Hydrochloride Injection) | HOSPIRA_00356713 | HOSPIRA_00356721 | F, H, P | |
| | 3/6/2015 | Precedex Overview Presentation Deck | HOSPIRA_00500884 | HOSPIRA_00500901 | F, H, K, S | H, R |
| | | 20 mL Precedex Premix Launch | HOSPIRA_00501917 | HOSPIRA_00501944 | F, H, P, R, K | H, R |
| | | Staging Precedex Premix Conversions | HOSPIRA_00502426 | HOSPIRA_00502428 | F, H, P, R, K | H, R |
| | | Strong Finish to 2014 Slide | HOSPIRA_00502505 | HOSPIRA_00502505 | F, H, P, R, K | H, R |
| | | Precedex Premix Return to Market Deck | HOSPIRA_00503023 | HOSPIRA_00503037 | F, H, P, R, K | H, R |
| | 6/5/2013 | Precedex Premix Launch Update Deck | HOSPIRA_00504215 | HOSPIRA_00504230 | F, H, P, R, K | H, R |
| | 4/2-3/2013 | Precedex Premix Launch Deck | HOSPIRA_00504816 | HOSPIRA_00504861 | F, H, P, R, K | H, R |
| | 7/2009 | Decision Development Inc., Precedex® Pre-Mix Research Presentation to Hospira, Inc. (July 2009) | HOSPIRA_00507545 | HOSPIRA_00507585 | K, H | H, R |
| | 1/24/2011 | Launch of Premixed Precedex Market research findings report deck | HOSPIRA_00507586 | HOSPIRA_00507626 | F, H, P, R, K | H, R |
| | 8/22/2012 | Precedex US Commercial Deep Dive Deck | HOSPIRA_00543429 | HOSPIRA_00543457 | V, F | H, R |
| | | Development Report for Precedex Injection - Hospira Scientific Report (4-2-2010) | HOSPIRA_00545097 | HOSPIRA_00545168 | F, K | H, R |
| | 6/2014 | Decision Development Inc. Presentation - 2014 | HOSPIRA_00595931 | HOSPIRA_00595994 | F, H, P, R, K | H, R |
| | | Premix Market Research Deck | HOSPIRA_00606976 | HOSPIRA_00606992 | F, H, P, R, K | H, R |
| | | 2013 Kickoff Deck | HOSPIRA_00607301 | HOSPIRA_00607327 | F, H, P, R, K | H, R |
| | | Barr, et al., Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit, Critical Care Medicine, 41(1):263 (2013) | HOSPIRA_00610077 | HOSPIRA_00610120 | H, K | H, R |
| | | Precedex Premix Deck | HOSPIRA_00610467 | HOSPIRA_00610501 | F, H, P, R, K | H, R |
| | | 2014 Plan - Precedex Promo Budget excel | HOSPIRA_00658437 | HOSPIRA_00658462 | F, H, P, R, K | H, R |
| | 2/2008 | Precedex Qualitative Market Research Deck - Decision Development Inc 2008 | HOSPIRA_00661235 | HOSPIRA_00661272 | H, K | H, R |
| | | Hospira Stability Data | HOSPIRA_00737251 | HOSPIRA_00737276 | | H, R, Y |
| | | Letter to customer re Precedex Premix approval | HOSPIRA_00801235 | HOSPIRA_00801269 | F, H, K | H, R |
| | 2/11/2013 | Development Report for Precedex Injection 4 mcg-mL initiated by Skora Rev 2.0 | HOSPIRA_00856539 | HOSPIRA_00856610 | F, H, K, R | H, R |
| | | Development Report for Precedex LE Injection Rev 1.0 authored by Roychowdhury | HOSPIRA_00877283 | HOSPIRA_00877323 | F, H, P | H, R, F |
| | 8/11/2014 | Precedex 20 mL Premix launch discussion | HOSPIRA_00879052 | HOSPIRA_00879056 | F, H, P, R, K | H |
| | 3/12/2013 | Precedex Premix Launch Readiness Review | HOSPIRA_00885114 | HOSPIRA_00885125 | F, H, P, R, K | H |
| | 6/2013 | Precedex™ Label, updated June 2013 | HOSPIRA_00901665 | HOSPIRA_00901688 | F, H, P, R | H, R |
| | 12/17/1999 | Approval letter re NDA 21-038 | HOSPIRA_00903128 | HOSPIRA_00903145 | F, H, P | H |

Joint Exhibit List

| JTX | Document Date | Description | Beg Bates | End Bates | Hospira Objections | FK Objections |
|-----|-------------------------|--|------------------|-------------------|--------------------|---------------|
| | | Development Report for Precedex LE Injection 4ug/mL, 20 mL, 50 mL and 100 mL | HOSPIRA_01098606 | HOSPIRA_01098646 | F, H, P, R, K | H |
| | 3/13/2013 | Precedex Injection March 13, 2013 A Day that will go Down in History | HOSPIRA_01124546 | HOSPIRA_01124549 | F, H, P, R | H, F |
| | | Laboratory Notebook Excerpt - 00737 | HOSPIRA_01138634 | HOSPIRA_01138636 | F, K | H |
| | | Laboratory Notebook Excerpt - 00738 | HOSPIRA_01138637 | HOSPIRA_01138653 | F, K | H |
| | | Chart re Precedex Line Extension | HOSPIRA_01138677 | HOSPIRA_01138679 | F, K, H | H |
| | 9/22/2006 | Hospira Product Development Concept Proposal | HOSPIRA_01140245 | HOSPIRA_01140253 | D, F, K, H | H |
| | 3/7/2008 & 3/14/2008 | Precedex Line Extension Meeting Minutes | HOSPIRA_01145154 | HOSPIRA_01145156 | F, K | H |
| | 8/30/2007 | Precedex Line Extension Meeting Minutes | HOSPIRA_01146197 | HOSPIRA_01146198 | F, K | H |
| | | Precedex Line Extension Meeting Minutes (2-2-2007) | HOSPIRA_01146265 | HOSPIRA_001146268 | F, K | H |
| | 10/31/2006 | Email re Precedex Line Extension Core Team Meeting Minutes for 10/27/06 | HOSPIRA_01150882 | HOSPIRA_01150883 | F, H, P, R | H, F |
| | 7/14/2004 | Letter enclosing Amendment to License and Supply Agreement dated September 9, 1994 | HOSPIRA_01768591 | HOSPIRA_01768600 | F, H, P | H |
| | 10/27/2006 | NDA 21-038 Supplement | HOSPIRA_01846472 | HOSPIRA_01846521 | F, H, P | H, F |
| | 10/21/2008 | Decision Development Inc. script | HOSPIRA_01982846 | HOSPIRA_01982855 | F, H, P | H, F |
| | 5/15/2003 | Fax enclosing Amendment to Orion License Agreement | HOSPIRA_02013574 | HOSPIRA_02013730 | F, H, P | H |
| | 6/12/2009 | Market Research Supplier Agreement | HOSPIRA_02119137 | HOSPIRA_02119141 | F, H, P | H, F |
| | 11/14/2007 | Letter re Decision Development Inc. engagement with Hospira, Inc. | HOSPIRA_02156189 | HOSPIRA_02156193 | F, H, P | H, F |
| | 8/2015 | US Pharma August 2015 Financial Review | HOSPIRA_02481930 | HOSPIRA_02481958 | F, H, P, R, K | H, R, AU, F |
| | 8/27/2015 | Email re Precedex Plan V2.0 | HOSPIRA_02482111 | HOSPIRA_02482113 | F, H, K, S | H, R, AU, F |
| | 8/28/2013 | Precedex Premix Return to Market Deck | HOSPIRA_02482796 | HOSPIRA_02482810 | F, H, P, R, K | H, R, AU, F |
| | 5/23/2013 | Precedex Premix Meeting Deck | HOSPIRA_02482812 | HOSPIRA_02482819 | F, H, P, R, K | H, R, AU, F |
| | 9/8/2014 | Email re ACCS LEADERSHIP NEWS: SEPTEMBER 8, 2014 EDITION | HOSPIRA_02483045 | HOSPIRA_02483047 | F, H, P, R | H, R, AU, F |
| | | Letter re production of Precedex Premix | HOSPIRA_02484931 | HOSPIRA_02484931 | F, H, P, R, K | H, R, AU, F |
| | 5/16/2013 | Release re HOSPIRA announces allocation for Precedex | HOSPIRA_02485552 | HOSPIRA_02485552 | F, H, P, R, K | H, R, AU, F |
| | | Talking Points - Precedex Premix Constrained Supply | HOSPIRA_02485615 | HOSPIRA_02485615 | F, H, P, R, K | H, R, AU, F |
| | | Sales data through Q2 2015 | HOSPIRA_02497376 | HOSPIRA_02497376 | F, H, P, R, K | H |
| | | Laboratory Notebook - 01123 | HOSPIRA_02497451 | HOSPIRA_02497519 | F, K | H |
| | | Laboratory Notebook - 01572 | HOSPIRA_02497608 | HOSPIRA_02497769 | F, K | H |
| | | Laboratory Notebook - 01729 | HOSPIRA_02497770 | HOSPIRA_02497936 | F, K | H |
| | | Laboratory Notebook - 01236 | HOSPIRA_02497937 | HOSPIRA_02498025 | F, K | H |
| | | Laboratory Notebook - 02282 | HOSPIRA_02498026 | HOSPIRA_02498189 | V, F | H |
| | | Laboratory Notebook - 02294 | HOSPIRA_02498190 | HOSPIRA_02498344 | V, F | H |
| | 10/27/2016 | Sales data through Q2 2016 | HOSPIRA_02498345 | HOSPIRA_02498345 | F, H, P, R, K | H |
| | 5/24/2016 | Precedex Premix Value Proposition Evaluation | HOSPIRA_02498510 | HOSPIRA_02498543 | F, H, P, R, K | H, R, AU, F |
| | | Precedex margin and price data | HOSPIRA_02498544 | HOSPIRA_02498544 | F, H, P, R, K | H, R, AU, F |
| 01 | 5/1999 | FDA, Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics | HOSPIRA_02498545 | HOSPIRA_02498600 | F, H, P | H |
| 2 | | Webb, P. et al., "Ensure Safety, Efficacy of Ready-to-Use IV Drug Products," PFQ Vol. 11, No. 6, Oct/Nov. 2009 | HOSPIRA_02498601 | HOSPIRA_02498604 | F, H, P | H |
| 3 | 4/2004 | Dahlstrom et al., "Impact of polymer surface affinity of novel antifouling agents," 86(1) BIOTECH. BIOENG. 1-8 (Apr. 2004) | HOSPIRA_02498605 | HOSPIRA_02498612 | F, H, P | H |
| 4 | | J. Anes, Use of Plastics for Parenteral Packaging | HOSPIRA_02498613 | HOSPIRA_02498670 | F, H, P | H |
| 5 | | Precedex Prescribing Information (rev. 5/2016) | HOSPIRA_02498671 | HOSPIRA_02498693 | F, P | |
| 6 | 3/2016 | Prescribing Information Precedex | HOSPIRA_02501013 | HOSPIRA_02501035 | F, H, P, D | |
| 7 | 7/28/2004 | Recordation Form Cover Sheet Patents Only, Reel 014921 / Frame 0536 | HOSPIRA_02501036 | HOSPIRA_02501063 | K | H, R, AU, F |
| 8 | 4/16/2004 | Tax Sharing Agreement between Abbott Laboratories and Hospira Inc. | HOSPIRA_02501064 | HOSPIRA_02501092 | F, H, P | H, R, AU, F |

Joint Exhibit List

| JTX | Document Date | Description | Beg Bates | End Bates | Hospira Objections | FK Objections |
|-----|---------------|--|------------------|------------------|--------------------|---------------|
| 9 | 4/12/2004 | Separation and Distribution Agreement Abbott Laboratories and Hospira Inc | HOSPIRA_02501093 | HOSPIRA_02501570 | F, H, P, D | |
| 0 | | Dexmedetomidine License and Supply Agreement Orion Corp and Abbott Laboratories | HOSPIRA_02501571 | HOSPIRA_02501705 | F, H, P | |
| 1 | | Chart re Net Sales | HOSPIRA_02501706 | HOSPIRA_02501706 | F, H, P, R, K | H, R, AU, F |
| 2 | | Chart re Medication Sales by each Medication | HOSPIRA_02501707 | HOSPIRA_02501707 | F, H, P, R, K | H, R, AU, F |
| 3 | 4/16/2004 | Letter to Shareholders and Information Statement | HOSPIRA_02501708 | HOSPIRA_02501826 | F, H, P | |
| 4 | | Boyd, Donald B., The Power of Computational Chemistry to Leverage Stress Testing of Pharmaceuticals (Ch. 12) (2005) | HOSPIRA_02501997 | HOSPIRA_02502068 | F, H, P | |
| 5 | | FDA.gov - Investigative New Drug (IND) Application | HOSPIRA_02502069 | HOSPIRA_02502074 | F, H, P | |
| 6 | | Impurities in Drug Substances and Drug Products | HOSPIRA_02502075 | HOSPIRA_02502081 | F, H, P | H, R, AU, F |
| 7 | | Guidance of Industry ANDAs: Stability Testing of Drug Substances and Products (May 2014) | HOSPIRA_02502082 | HOSPIRA_02502098 | F, H, P | H, R, AU, F |
| 8 | | Guidance for Industry Q1A(R2) Stability Testing of New Drug Substances and Products (November 2003) | HOSPIRA_02502099 | HOSPIRA_02502123 | F, H, P | H, R, AU, F |
| 9 | | BIO, Clinical Development Success Rates 2006-2015 (https://www.bio.org/sites/default/files/Clinical%20Development%20Success%20Rates%2006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf) | HOSPIRA_02502144 | HOSPIRA_02502171 | H, F, K | H, R, AU, F |
| 0 | | Stability of dexmedetomidine in polypropylene syringes | HOSPIRA_02502192 | HOSPIRA_02502194 | H, K | |
| 1 | | Ativan (lorazepam) Injection Label | HOSPIRA_02502195 | HOSPIRA_02502211 | Au, F, H, P, R | H, R |
| 2 | 3/25/2010 | Bioalliance, WO 2010/031819 A1 | HOSPIRA_02502212 | HOSPIRA_02502277 | F, H, P, R | |
| 3 | | C.E. Blogg, M.A.E. Ramsay, and J.D. Jarvis, "Infection Hazard from Syringes," Br. J. Anaesth., 46, pp. 260-262 (1974) | HOSPIRA_02502278 | HOSPIRA_02502280 | K, H | |
| 4 | 4/2017 | Diprivan Label, Revised: April 2017 | HOSPIRA_02502281 | HOSPIRA_02502334 | Au, F, H, P, R | H, R |
| 5 | 3/25/2011 | FDA, Advisory to Drug Manufacturers: Formation of Glass Lamellae in Certain Injectable Drugs (Mar. 25, 2011) | HOSPIRA_02502335 | HOSPIRA_02502337 | F, H, K | H, AU, F |
| 6 | | Anesthesiology Core Review: Chap. 55 (http://accessanesthesiology.mhmedical.com/content.aspx?bookid=974&sectionid=61587929) | HOSPIRA_02502338 | HOSPIRA_02502340 | Au, F, H, P, R | H, R |
| 7 | | FDA Orange Book listing re Precedex - https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=004&Appl_No=021038&Apppl_type=N | HOSPIRA_02502347 | HOSPIRA_02502348 | Au, F, H, P, R, X | |
| 8 | | FDA.gov, Information for Outsourcing Facilities (https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm393571.htm) | HOSPIRA_02502377 | HOSPIRA_02502379 | F, H, K | H, R |
| 9 | | PharMEDium, About PharMEDium (https://www.pharmedium.com/company/) | HOSPIRA_02502389 | HOSPIRA_02502396 | H, K | H, R, AU, F |
| 0 | | PharMEDium, Critical Care (https://www.pharmedium.com/compounded-services/critical-care/) | HOSPIRA_02502397 | HOSPIRA_02502404 | F, H, P | H, R, AU, F |
| 1 | | Midazolam Label, Revised March 2017 | HOSPIRA_02502405 | HOSPIRA_02502456 | F, H, P, R | H, R |
| 2 | 7/2008 | PhRMA, "The Facts About Pharmaceutical Marketing & Promotion," July 2008, http://www.phrma.org/sites/default/files/pdf/marketing_and_promotion_facts_071108_final.pdf | HOSPIRA_02502457 | HOSPIRA_02502480 | F, H, P | H, R, AU, F |
| 3 | 2009 | Rahul Guha, Jian Li, and Andrea L. Scott, "The Economics of Commercial Success in Pharmaceutical Patent Litigation," Landslide 1.5 (2009) | HOSPIRA_02502481 | HOSPIRA_02502485 | Au, F, H, P, R | H, R, AU, F |
| 4 | | U.S. Patent No. 4,910,214 | HOSPIRA_02502487 | HOSPIRA_02502491 | F, H, P, R | |
| 5 | | US Patent 9,649,296 | HOSPIRA_02502492 | HOSPIRA_02502497 | F, H, P | R |
| 6 | | US Patent 9,717,796 | HOSPIRA_02502498 | HOSPIRA_02502503 | F, H, P | R |

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.